Site Map

Fanconi anemia

Fanconi's anemia; Anemia - Fanconi's

Fanconi anemia is a rare disease passed down through families (inherited) that mainly affects the bone marrow. It results in decreased production of all types of blood cells.

This is the most common inherited form of aplastic anemia.

Fanconi anemia is different from Fanconi syndrome, a rare kidney disorder.

Images

Formed elements of blood

Causes

Fanconi anemia is due to an abnormal gene that damages cells, which keeps them from repairing damaged DNA.

To inherit Fanconi anemia, a person must get one copy of the abnormal gene from each parent.

The condition is most often diagnosed in children between 3 and 14 years old.

Symptoms

People with Fanconi anemia have lower-than-normal numbers of white blood cells, red blood cells, and platelets (cells that help the blood clot).

Not enough white blood cells can lead to infections. A lack of red blood cells may result in fatigue (anemia).

A lower-than-normal amount of platelets may lead to excess bleeding.

Most people with Fanconi anemia have some of these symptoms:

Other possible symptoms:

Exams and Tests

Common tests for Fanconi anemia include:

Pregnant women may have amniocentesis or chorionic villous sampling to diagnose the condition in their unborn child.

Treatment

People with mild to moderate blood cell changes who do not need a transfusion may only need regular check-ups and blood count checks. The health care provider will closely monitor the person for other cancers. These may include leukemia or cancers of the head, neck, or urinary system.

Medicines called growth factors (such as erythropoietin, G-CSF, and GM-CSF) can improve blood counts for a short while.

A bone marrow transplant can cure the blood count problems of Fanconi anemia. (The best bone marrow donor is a brother or sister whose tissue type matches the person affected by Fanconi anemia.)

People who have had a successful bone marrow transplant still need regular check-ups because of the risk for additional cancers.

Hormone therapy combined with low doses of steroids (such as hydrocortisone or prednisone) is prescribed to those who do not have a bone marrow donor. Most people respond to hormone therapy. But everyone with the disorder will quickly get worse when the medicines are stopped. In most cases, these medicines eventually stop working.

Additional treatments may include:

Most people with this condition visit a doctor on regular basis, specializing in treating:

Outlook (Prognosis)

The survival rates vary from person to person. The outlook is poor in those with low blood counts. New and improved treatments, such as bone marrow transplants, have likely improved survival.

People with Fanconi anemia are more likely to develop several types of blood disorders and cancers. These may include leukemia, myelodysplastic syndrome, and cancer of the head, neck, or urinary system.

Women with Fanconi anemia who become pregnant should be watched carefully by a specialist. Such women often need transfusions throughout pregnancy.

Men with Fanconi anemia have decreased fertility.

Possible Complications

Complications of Fanconi anemia may include:

Prevention

Families with a history of this condition can have genetic counseling to better understand their risk.

Vaccination can reduce certain complications, including pneumococcal pneumonia, hepatitis, and varicella infections.

People with Fanconi anemia should avoid cancer-causing substances (carcinogens) and have regular check-ups to screen for cancer.

References

Dror Y. Inherited bone marrow failure syndromes. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 29.

Lissauer T, Carroll W. Haematological disorders. In: Lissauer T, Carroll W, eds. Illustrated Textbook of Paediatrics. 6th ed. Philadelphia, PA: Elsevier; 2022:chap 23.

Vlachos A, Nash M, Lipton JM. Bone marrow failure. In: Fish JD, Lipton JM, Lanzkowsky P eds. Lanzkowsky's Manual of Pediatric Hematology and Oncology. 7th ed. Cambridge, MA: Elsevier Academic Press; 2022:chap 6.

BACK TO TOP

Review Date: 1/25/2022  

Reviewed By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo
Health Content Provider
06/01/2025

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complied with the HONcode standard for trustworthy health information from 1995 to 2022, after which HON (Health On the Net, a not-for-profit organization that promoted transparent and reliable health information online) was discontinued.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2024 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.